{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T05:11:53Z","timestamp":1772946713308,"version":"3.50.1"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002660","name":"Islamic Azad University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002660","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010679","name":"Pasteur Institute of Iran","doi-asserted-by":"publisher","award":["1161 (Covid-19"],"award-info":[{"award-number":["1161 (Covid-19"]}],"id":[{"id":"10.13039\/501100010679","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["New Microbes and New Infections"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.nmni.2025.101634","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T06:41:10Z","timestamp":1756795270000},"page":"101634","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Enhanced immunogenicity of COVID-19 RBD fused to mutant scorpion's phospholipase D for vaccine development"],"prefix":"10.1016","volume":"67","author":[{"given":"Mohammad-Reza","family":"Zareinejad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4839-5123","authenticated-orcid":false,"given":"Mahdi","family":"Behdani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Taghi","family":"Goodarzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akbar","family":"Oghalaie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Hosseininejad-Chafi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamran","family":"Pooshang-Bagheri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delavar","family":"Shahbazzadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmni.2025.101634_bib1","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1002\/jmv.25986","article-title":"Evaluation of SARS-CoV-2 neutralizing antibodies using a CPE-based colorimetric live virus micro-neutralization assay in human serum samples","volume":"92","author":"Manenti","year":"2020","journal-title":"J Med Virol"},{"key":"10.1016\/j.nmni.2025.101634_bib2","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1039\/D1CB00200G","article-title":"A COVID-19 vaccine candidate composed of the SARS-CoV-2 RBD dimer and Neisseria meningitidis outer membrane vesicles","volume":"3","author":"Santana-Mederos","year":"2022","journal-title":"RSC Chem Biol"},{"key":"10.1016\/j.nmni.2025.101634_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.104739","article-title":"Protein-protein conjugation enhances the immunogenicity of SARS-CoV-2 receptor-binding domain (RBD) vaccines","volume":"25","author":"Scaria","year":"2022","journal-title":"iScience"},{"key":"10.1016\/j.nmni.2025.101634_bib4","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/s41587-020-0631-z","article-title":"A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction","volume":"38","author":"Tan","year":"2020","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.nmni.2025.101634_bib5","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1021\/acschembio.1c00272","article-title":"SARS-CoV-2 RBD-tetanus toxoid conjugate vaccine induces a strong neutralizing immunity in preclinical studies","volume":"16","author":"Valdes-Balbin","year":"2021","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.nmni.2025.101634_bib6","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.bbrc.2020.02.071","article-title":"Structure analysis of the receptor binding of 2019-nCoV","volume":"525","author":"Chen","year":"2020","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.nmni.2025.101634_bib7","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41586-020-2180-5","article-title":"Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor","volume":"581","author":"Lan","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.nmni.2025.101634_bib8","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41586-020-2179-y","article-title":"Structural basis of receptor recognition by SARS-CoV-2","volume":"581","author":"Shang","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.nmni.2025.101634_bib9","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.nmni.2025.101634_bib10","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00127-20","article-title":"Receptor recognition by the novel coronavirus from wuhan: an analysis based on decade-long structural studies of SARS coronavirus","volume":"94","author":"Wan","year":"2020","journal-title":"J Virol"},{"key":"10.1016\/j.nmni.2025.101634_bib11","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s12879-023-08079-1","article-title":"Phase II randomized, double blind, placebo controlled, clinical trial of safety and immunogenicity of an inactivated SARS-CoV-2 vaccine FAKHRAVAC in adults aged 18-70 years","volume":"23","author":"Gholami","year":"2023","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.nmni.2025.101634_bib12","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41577-020-00434-6","article-title":"Immunological considerations for COVID-19 vaccine strategies","volume":"20","author":"Jeyanathan","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.nmni.2025.101634_bib13","article-title":"Is smaller better? Vaccine targeting recombinant receptor-binding domain might hold the key for mass production of effective prophylactics to fight the COVID-19 pandemic","volume":"5","author":"Muhuri","year":"2020","journal-title":"Signal Transduct Tar"},{"key":"10.1016\/j.nmni.2025.101634_bib14","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.cell.2020.09.037","article-title":"Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology","volume":"183","author":"Piccoli","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.nmni.2025.101634_bib15","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s41586-020-2599-8","article-title":"A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity","volume":"586","author":"Yang","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.nmni.2025.101634_bib16","doi-asserted-by":"crossref","DOI":"10.1038\/s41421-020-00199-1","article-title":"Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement","volume":"6","author":"Zang","year":"2020","journal-title":"Cell Discov"},{"key":"10.1016\/j.nmni.2025.101634_bib17","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1056\/NEJMoa2026920","article-title":"Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine","volume":"383","author":"Keech","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmni.2025.101634_bib18","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1111\/all.15305","article-title":"Vaccine based on folded receptor binding domain-PreS fusion protein with potential to induce sterilizing immunity to SARS-CoV-2 variants","volume":"77","author":"Gattinger","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.nmni.2025.101634_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25071673","article-title":"Novel mutant phospholipase D from Hemiscorpius lepturus acts as A highly immunogen in BALB\/c mice against the lethality of scorpion venom","volume":"25","author":"Soleimani Moez","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.nmni.2025.101634_bib20","doi-asserted-by":"crossref","first-page":"500","DOI":"10.4103\/RPS.RPS_93_23","article-title":"Expression and purification of SARS-CoV-2 receptor binding domain in Escherichia coli for diagnostic and therapeutic purposes","volume":"19","author":"Ghaderi","year":"2024","journal-title":"Res Pharm Sci"},{"key":"10.1016\/j.nmni.2025.101634_bib21","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41467-020-20247-4","article-title":"Neutralizing antibody titres in SARS-CoV-2 infections","volume":"12","author":"Lau","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.nmni.2025.101634_bib22","doi-asserted-by":"crossref","first-page":"583","DOI":"10.3181\/00379727-112-28111","article-title":"A plaque assay for respiratory syncytial virus","volume":"112","author":"Kisch","year":"1963","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1016\/j.nmni.2025.101634_bib23","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.4110\/in.2021.21.e39","article-title":"SARS-CoV-2 antibody neutralization assay platforms based on epitopes sources: live virus, pseudovirus, and recombinant S glycoprotein RBD","volume":"21","author":"Septisetyani","year":"2021","journal-title":"Immune Netw"},{"key":"10.1016\/j.nmni.2025.101634_bib24","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41598-023-50822-w","article-title":"Omicron-specific and bivalent omicron-containing vaccine candidates elicit potent virus neutralisation in the animal model","volume":"14","author":"Abdoli","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.nmni.2025.101634_bib25","volume":"11","author":"Barkhordar","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.nmni.2025.101634_bib26","doi-asserted-by":"crossref","first-page":"4220","DOI":"10.1016\/j.vaccine.2022.05.082","article-title":"Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: open label phase I and phase IIa clinical trials","volume":"40","author":"Eugenia-Toledo-Romani","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.nmni.2025.101634_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e20555","article-title":"Evaluation of PastoCovac plus vaccine as a booster dose on vaccinated individuals with inactivated COVID-19 vaccine","volume":"9","author":"Farahmand","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.nmni.2025.101634_bib28","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ijid.2022.11.016","article-title":"Open-label phase I\/II clinical trial of SARS-CoV-2 receptor binding domain-tetanus toxoid conjugate vaccine (FINLAY-FR-2) in combination with receptor binding domain-protein vaccine (FINLAY-FR-1A) in children","volume":"126","author":"Puga-Gomez","year":"2023","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.nmni.2025.101634_bib29","article-title":"PastoCovac and PastoCovac plus as protein subunit COVID-19 vaccines led to great humoral immune responses in BBIP-CorV immunized individuals","volume":"13","author":"Ramezani","year":"2023","journal-title":"Sci Rep-Uk"},{"key":"10.1016\/j.nmni.2025.101634_bib30","article-title":"Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-Plus: a double-blind, randomised, placebo-controlled phase 3 clinical trial","volume":"18","author":"Toledo-Roman\u00ed","year":"2023","journal-title":"Lancet Reg Health Am"},{"key":"10.1016\/j.nmni.2025.101634_bib31","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.bbrc.2021.04.056","article-title":"Production in Escherichia coli of recombinant COVID-19 spike protein fragments fused to CRM197","volume":"558","author":"Bellone","year":"2021","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.nmni.2025.101634_bib32","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/s41423-021-00658-z","article-title":"Recombinant vaccine containing an RBD-Fc fusion induced protection against SARS-CoV-2 in nonhuman primates and mice","volume":"18","author":"Sun","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.nmni.2025.101634_bib33","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.toxicon.2020.05.010","article-title":"Complete neutralization of the lethality of Hemiscorpius lepturus crude venom by a novel anti-recombinant phospholipase D1 IgGs","volume":"183","author":"Torabi","year":"2020","journal-title":"Toxicon"}],"container-title":["New Microbes and New Infections"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2052297525000733?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2052297525000733?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T14:59:21Z","timestamp":1772895561000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2052297525000733"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":33,"alternative-id":["S2052297525000733"],"URL":"https:\/\/doi.org\/10.1016\/j.nmni.2025.101634","relation":{},"ISSN":["2052-2975"],"issn-type":[{"value":"2052-2975","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhanced immunogenicity of COVID-19 RBD fused to mutant scorpion's phospholipase D for vaccine development","name":"articletitle","label":"Article Title"},{"value":"New Microbes and New Infections","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmni.2025.101634","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101634"}}